BPC-157 + TB-500 Blend: Ingredients, Sizes, and Research
Explore the BPC-157/TB-500 blend in 5 mg + 5 mg and 10 mg + 10 mg formats, with ingredient research, evidence limits, and component concentration calculations.
Quick facts
| Product | BPC-157 + TB-500 Blend |
|---|---|
| 10 mg formulation | 5 mg BPC-157 + 5 mg TB-500 fragment |
| 20 mg formulation | 10 mg BPC-157 + 10 mg TB-500 fragment |
| Nominal mass ratio | 1:1 for both sizes |
| Evidence distinction | Component studies do not validate the complete blend |
| Hero product | BPC-157 + TB-500 Blend |
Hero’s BPC-157 + TB-500 blend combines two research peptides. The export lists total-size options of 10 mg and 20 mg. The 10 mg version contains nominal 5 mg of each ingredient, and the 20 mg version contains nominal 10 mg of each ingredient. Understanding those amounts is the first step toward describing the product accurately and calculating a laboratory solution.
The ingredients have different structures and research histories. A fixed blend brings them into one preparation, but it does not establish a shared mechanism or a proven interaction. This guide explains the composition, the relevant evidence boundaries, and the calculations that keep total and component concentrations separate.
BPC-157 + TB-500 Blend. View catalog product
Origin story: what the BPC-157 + TB-500 blend name describes
BPC-157 + TB-500 blend is a catalog name rather than the name of a single peptide. The 10 mg format combines 5 mg of each ingredient. The 20 mg format combines 10 mg of each ingredient. For the documented 20 mg formulation, 20 mg refers to combined nominal mass, not to 20 mg of each ingredient. The 10 mg variant contains 5 mg of each ingredient, not 10 mg of each.
Hero identifies its TB-500 ingredient as a thymosin beta-4 fragment. Keep that distinction in the materials record. Full-length thymosin beta-4, a defined fragment, and an unspecified product carrying the TB-500 name should not be treated as chemically identical.
A fixed formulation also fixes the nominal mass ratio. If a research question requires different relative concentrations, that question cannot be answered by changing only the final volume of this blend. Dilution changes both component concentrations together.
How BPC-157 + TB-500 blend is built: two equal nominal masses
Both formats use a 1:1 nominal mass ratio. Their component amounts are shown separately below.
| Catalog format | BPC-157 | TB-500 fragment | Total nominal material | Mass ratio |
|---|---|---|---|---|
| 10 mg | 5 mg | 5 mg | 10 mg | 1:1 |
| 20 mg | 10 mg | 10 mg | 20 mg | 1:1 |
The 1:1 ratio is a mass ratio. It does not establish equal molecule counts, equal receptor activity, or equal contribution to a measured response. A molar calculation requires the appropriate molecular-weight basis for each documented ingredient.
The BPC-157 guide and TB-500 guide explain the individual materials. Consult them alongside the blend specification rather than using either ingredient’s description as a complete description of BPC-157 + TB-500 blend.
A mixture also raises questions that do not arise from the label alone. Do the components remain compatible under the selected preparation conditions? Does the analytical method resolve them? Does the intended assay distinguish a component response from a combination response?
Key research: ingredient findings and blend questions
A BPC-157 primary study examined tendon explant outgrowth, fibroblast migration, and survival in preclinical experiments. Those endpoints provide background for tissue-related research questions. The study did not evaluate Hero BPC-157 + TB-500 blend (Chang et al., 2011).
An analytical TB-500 study characterized an acetylated fragment corresponding to residues 17-23 of thymosin beta-4 in a tested preparation. That work illustrates why exact identity matters; it does not establish a biological result for this two-ingredient blend (Esposito et al., 2012).
A separate publication discusses activities associated with different sequence regions of thymosin beta-4. It provides context for the parent peptide and fragments, while leaving the exact experimental material essential to interpretation (Sosne et al., 2010).
For a combination experiment, appropriate controls would depend on the hypothesis. A design might compare the individual components, the mixture, and the vehicle under matched conditions. A result from the mixture alone cannot identify which component contributed to the response.
Synergy is a more specific claim still. It requires a defined expectation for the combined response and a suitable interaction analysis. Two ingredients appearing in related research discussions do not establish that expectation or satisfy the test.
Weak spots: a blend needs its own characterization
The cited literature supplies background, not direct validation of BPC-157 + TB-500 blend’s safety, clinical effectiveness, or solution stability. As of November 17, 2026, this guide does not establish an approved clinical use for Hero BPC-157 + TB-500 blend.
Exact TB-500 fragment identity remains a documentation question. The supplied handoff establishes the fragment designation, but not every sequence or terminal detail. Verify those details against the current lot specification when they matter to the planned method.
A general purity statement also has limits for a mixture. Determine which component identities were assessed, whether the method separated the ingredients, and whether reported quantities are nominal or analytically measured. One percentage should not be assumed to answer all three questions.
The GLOW blend guide provides a composition comparison: Hero GLOW includes a third ingredient, GHK-Cu. The two products differ in formulation, so findings or preparation assumptions should not be transferred simply because both include BPC-157 and TB-500.
Handling BPC-157 + TB-500 blend in the lab: calculate each ingredient
Choose preparation conditions from the lot documentation and the validated requirements of the complete formulation. The examples below are arithmetic only. They do not select a solvent, demonstrate compatibility, or establish a storage interval.
| Format and hypothetical final volume | BPC-157 | TB-500 fragment | Combined material |
|---|---|---|---|
| 10 mg format, 2 mL | 2.5 mg/mL | 2.5 mg/mL | 5 mg/mL |
| 10 mg format, 4 mL | 1.25 mg/mL | 1.25 mg/mL | 2.5 mg/mL |
| 20 mg format, 2 mL | 5 mg/mL | 5 mg/mL | 10 mg/mL |
| 20 mg format, 4 mL | 2.5 mg/mL | 2.5 mg/mL | 5 mg/mL |
For the 20 mg format at a hypothetical 2 mL final volume, calling the preparation 10 mg/mL BPC-157 would be incorrect. That value is the combined concentration; the nominal concentration of each ingredient is 5 mg/mL. Label both separately.
The calculator can check each component using its nominal mass and the shared final volume. Record composition, final volume, solvent, preparation date, and subsequent dilutions in the same laboratory record.
Hero’s supplied catalog names Northfield Analytical for HPLC and mass-spectrometry testing. Read the matching blend report to identify the tests actually performed. The COA guide explains how to distinguish identity, purity, and quantified content.
BPC-157 + TB-500 blend peptide blend FAQ
What is in Hero BPC-157 + TB-500 blend?
The 10 mg format contains nominal 5 mg of each ingredient, while the 20 mg format contains nominal 10 mg of each ingredient.
Does a 1:1 ratio mean equal biological effects?
No. It describes nominal mass proportions. Molecular amounts and biological responses require separate calculations or measurements.
Can dilution change the ingredient ratio?
A simple dilution changes both nominal concentrations together while retaining the specified ratio, assuming a homogeneous preparation without differential losses.
What is Hero’s BPC-157 + TB-500 blend?
Hero’s BPC-157 + TB-500 blend is Hero Peptides’ two-ingredient research blend, listed in 10 mg and 20 mg total-size options. Consult the product listing and matching lot report for supplied specifications.
BPC-157 + TB-500 Blend. View catalog product
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774-780. Source.
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4:733-738. Source.
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24:2144-2151. Source.
